- Home
- HCAI vs ANNX Comparison
HCAI vs ANNX Comparison
Compare HCAI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCAI
- ANNX
- Stock Information
- Founded
- HCAI 2004
- ANNX 2011
- Country
- HCAI China
- ANNX United States
- Employees
- HCAI N/A
- ANNX N/A
- Industry
- HCAI Miscellaneous manufacturing industries
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- HCAI Consumer Discretionary
- ANNX Health Care
- Exchange
- HCAI Nasdaq
- ANNX Nasdaq
- Market Cap
- HCAI 319.8M
- ANNX 362.4M
- IPO Year
- HCAI 2025
- ANNX 2020
- Fundamental
- Price
- HCAI $7.31
- ANNX $1.96
- Analyst Decision
- HCAI
- ANNX Strong Buy
- Analyst Count
- HCAI 0
- ANNX 5
- Target Price
- HCAI N/A
- ANNX $18.67
- AVG Volume (30 Days)
- HCAI 121.4K
- ANNX 1.8M
- Earning Date
- HCAI 01-01-0001
- ANNX 05-12-2025
- Dividend Yield
- HCAI N/A
- ANNX N/A
- EPS Growth
- HCAI N/A
- ANNX N/A
- EPS
- HCAI 0.11
- ANNX N/A
- Revenue
- HCAI $53,677,586.00
- ANNX N/A
- Revenue This Year
- HCAI N/A
- ANNX N/A
- Revenue Next Year
- HCAI N/A
- ANNX N/A
- P/E Ratio
- HCAI $77.40
- ANNX N/A
- Revenue Growth
- HCAI 534.84
- ANNX N/A
- 52 Week Low
- HCAI $3.70
- ANNX $1.73
- 52 Week High
- HCAI $10.97
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- HCAI N/A
- ANNX 33.91
- Support Level
- HCAI N/A
- ANNX $2.18
- Resistance Level
- HCAI N/A
- ANNX $2.75
- Average True Range (ATR)
- HCAI 0.00
- ANNX 0.25
- MACD
- HCAI 0.00
- ANNX -0.03
- Stochastic Oscillator
- HCAI 0.00
- ANNX 12.92
About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.